G2GBIO Inc. (456160.KQ)
KOSDAQ · KRW · Healthcare · Biotechnology
₩41,900 (-7.30%) as of
Key statistics
- Market cap
- 696.77B
- Dividend yield
- 0.00%
- 52-week range
- 22,400.00 – 124,000.00
- Profit margin
- 0.00%
- Volume
- 701.96k
About G2GBIO Inc.
G2GBIO Inc., a clinical-stage biotech company, provides pharmaceutical products. The company's pipeline products include GB-5001, GB-5001A, and GB-5112 for the treatment of Alzheimer's disease; GB-6002, an opioid drug that is used for post-operative pain treatment; GB-7001 for type-2 diabetes treatments; GB-5313 for the treatment of Osteoarthritis; GB-7101 and GB-7103 for the treatment of prostate cancer; GB-6201 and GB-6203 for androgenetic alopecia treatments; and GH-001 for the treatment of Hepatitis B. It also develops GB-2001 for animal castration; and GB-2006, an animal postoperative pain relief drug, which is in clinical trial stage. The company was founded in 2017 and is headquartered in Cheongju-si, South Korea.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Cheongju-si, South Korea
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.